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Abstract 
Genetic variants underlying complex traits, including disease susceptibility, are enriched within the 
transcriptional regulatory elements, promoters and enhancers. There is emerging evidence that 
regulatory elements associated with particular traits or diseases share similar patterns of 40 
transcriptional activity. Accordingly, shared transcriptional activity (coexpression) may help 
prioritise loci associated with a given trait, and help to identify underlying biological processes. 
Using cap analysis of gene expression (CAGE) profiles of promoter- and enhancer-derived RNAs 
across 1824 human samples, we have analysed coexpression of RNAs originating from trait-
associated regulatory regions using a novel quantitative method (network density analysis; NDA). 
For most traits studied, phenotype-associated variants in regulatory regions were linked to tightly-
coexpressed networks that are likely to share important functional characteristics. Coexpression 
provides a new signal, independent of phenotype association, to enable fine mapping of causative 
variants. The NDA coexpression approach identifies new genetic variants associated with specific 
traits, including an association between the regulation of the OCT1 cation transporter and genetic 50 
variants underlying circulating cholesterol levels. NDA strongly implicates particular cell types and 
tissues in disease pathogenesis. For example, distinct groupings of disease-associated regulatory 
regions implicate two distinct biological processes in the pathogenesis of ulcerative colitis; a further 
two separate processes are implicated in Crohn’s disease. Thus, our functional analysis of genetic 
predisposition to disease defines new distinct disease endotypes. We predict that patients with a 
preponderance of susceptibility variants in each group are likely to respond differently to 
pharmacological therapy. Together, these findings enable a deeper biological understanding of the 
causal basis of complex traits.  
Author Summary 
We discover that genetic variants associated with specific diseases have more in common with 60 
each other than we have previously seen. Specifically, variants associated with the same disease 
tend to be in parts of the genome that are turned on or off in similar complex patterns across many 
different cell types. We discover that genetic variants associated with specific diseases are found 
within regulatory elements that share patterns of expression. Specifically, variants associated with 
the same disease tend to be in parts of the genome that are turned on or off together in similar 
complex patterns across many different cell types. Knowing this helps us to find new variants 
associated with some diseases, and to better understand the genetic causes of other diseases. 
Furthermore, we discover that the genetic causes of inflammatory bowel disease fall into two 
distinct patterns, indicating that two aetiologically-distinct endotypes of this condition exist. Unlike 
other methods to learn about disease mechanisms from genetic information, our approach does 70 
not require any knowledge or assumptions about the genes themselves – it depends only on the 
patterns in which parts of the genome are activated in different cell types.  
Introduction 
Genome-wide association studies (GWAS) have considerable untapped potential to reveal new 
mechanisms of disease[1]. Variants associated with disease are over-represented in regulatory, 
rather than protein-coding, sequence; this enrichment is particularly strong in promoters and 
enhancers[2–4]. There is emerging evidence that gene products associated with a specific disease 
participate in the same pathway or process[5], and therefore share transcriptional control[6].  
We have recently shown that cell-type specific patterns of activity at multiple alternative 
promoters[7] and enhancers[3] can be identified using cap-analysis of gene expression (CAGE) to 80 
detect capped RNA transcripts, including mRNAs, lncRNAs and eRNAs[3,5]. In the FANTOM5 
project, we used CAGE to locate transcription start sites at single-base resolution and quantified 
the activity of 267,225 regulatory regions in 1824 human samples (primary cells, tissues, and cells 
following various perturbations)[8].  
Unlike analysis of chromatin modifications or accessibility, the CAGE sequencing used in 
FANTOM5 combines extremely high resolution in three relevant dimensions:  maximal spatial 
resolution on the genome, quantification of activity (transcript expression) over a wide dynamic 
range, and high biological resolution – quantifying activity in a much wider range of cell types and 
conditions than any previous study of regulatory variation[2,4]. Since a majority of human protein-
coding genes have multiple promoters[5] with distinct transcriptional regulation, CAGE also 90 
provides a more detailed survey of transcriptional regulation than microarray or RNAseq resources. 
Heritability of traits studied by some GWAS is substantially enriched in these FANTOM5 
promoters[9][10].  
Genes that are coexpressed are more likely to share common biology[11,12]. Similarly, regulatory 
regions that share activity patterns are more likely to contribute to the same biological pathways[5]. 
We have previously shown transcriptional activity of regulatory elements (both promoters and 
enhancers[3]) is associated with variable levels of expression arising at these elements in different 
cell types and tissues[5]. Informative regulatory networks can be derived from predicted 
transcription factor interactions with FANTOM5 regulatory regions[6]. We therefore use transcript 
expression here as a surrogate for transcriptional regulatory activity.  100 
In contrast to previous studies[6,13,14], we sought to explore the similarities in activity at disease-
associated sets of regulatory regions, rather than genes, and independent of transcription factor 
binding predictions. 
In order to determine whether coexpression of regulatory elements can provide additional 
information to prioritise genome-wide associations that would otherwise fall below genome-wide 
significance, we developed network density analysis (NDA). The NDA method combines genetic 
signals (disease association in a GWAS) with functional signals (correlation in promoter and 
enhancer-associated transcript levels measured by CAGE across numerous cell types and tissues, 
Fig 1), by mapping genetic signals onto a pairwise coexpression network of regulatory regions, and 
then quantifying the density of genetic signals within the network. Every expressed regulatory 110 
region that contains a GWAS SNP associated with a given trait is assigned a score quantifying its 
proximity in the network to every other regulatory region containing a GWAS SNP for that trait. We 
then identified specific cell types and tissues in which there is preferential activity of regulatory 
elements associated with selected disease-related phenotypes, thereby providing appropriate cell 
culture models for critical disease processes.  
 
Fig 1. Use of NDA to detect coexpression. (a) A subset of regulatory elements is identified containing disease-
associated SNPs. (b) The strength of the links between pairs of these regulatory regions is quantified, first as 
the Spearman correlation, then as the −𝒍𝒐𝒈𝟏𝟎p-value quantifying the probability, specific to this regulatory 
region, of a Spearman correlation of at least this strength arising by chance. This is determined from the 120 
empirical distribution of correlations between this regulatory region and all other regulatory regions in the entire 
network of all regulatory regions in the genome. (c) The subset of regulatory regions containing disease-
associated SNPs form an unexpectedly dense grouping in the network, but this may not be visible in a two-
dimensional representation (for illustration, this network shows all correlations between regulatory regions with 
Spearman 𝒓 > 𝟎. 𝟕, layout generated by the FMMM algorithm). The NDA score assigned to any one node is the 
sum of the links it shares with other nodes in the chosen subset (see Supplementary Methods for a full 
explanation). d) NDA scores from the input subset of regulatory elements are compared with NDA scores from 




For the purpose of this analysis, promoters identified in the FANTOM5 dataset were defined as the 
region from -300 bases to +100 bases from a transcription start site[15]. Previous analysis 
demonstrated that this covers the areas of maximal sequence conservation across species and the 
core region of transcription factor binding. Enhancers are widely transcribed across the human 
genome (eRNAs). Since eRNA TSS are considerably longer than promoter TSS (median 
length(IQR) 272(173-367) vs 15(9-26)), enhancers were defined by the range covered by eRNA 
transcription start sites. 
Coexpression algorithm 
For each GWAS study, SNPs were identified that lie within either a functional promoter or 140 
enhancer. Any promoter or enhancer that contained a variant putatively associated with a given 
phenotype was considered to be candidate phenotype-associated regulatory region. A pairwise 
matrix was then generated from the full FANTOM5 dataset of promoters and enhancers, in which 
each node is a regulatory region, and edges reflect the similarity in activity (expression) patterns 
arising at these regulatory regions, across different cell types and tissues. 
To test the hypothesis that regulatory regions genetically associated with a given phenotype are 
more likely to share activity patterns, we devised the NDA method, which quantifies the strength of 
coexpression among a chosen pool of putative phenotype-associated regulatory regions. This 
approach avoids arbitrary cut-offs between clusters (or “communities”) of nodes, and yields a 
single value for each node, quantifying the closeness with all other nodes in a particular subset 150 
(network density). NDA was used to integrate the putative association between a regulatory 
sequence and the phenotype of interest (indicated by the presence of a phenotype-associated 
SNP), with the coexpression similarity between this node with other nodes that are also putatively 
associated with the same phenotype. 
Principle of network density analysis (NDA) 
NDA integrates information from two distinct and independent sources: the relationships between 
nodes in the network, and the choice of subset. In the present work, nodes are regulatory regions, 
the subset is those regulatory regions that contain variants associated with a particular phenotype. 
Spearman’s rank correlation was chosen to quantify pairwise relationships, in view of the 
robustness of this measure in a variety of different distributions. However, the NDA approach is 160 
generalisable to any network of pairwise relationships. 
Within a network of all possible pairwise relationships between nodes, a subset of nodes is 
selected that share a particular characteristic. Within this subset of nodes, every pair of nodes is 
considered. Each relationship between two nodes is expressed as the −𝑙𝑜𝑔./  of the empirical 
probability of a relationship at least as strong occurring between the chosen node and another, 
randomly-chosen, node from anywhere in the network. These probabilities are specific to each 
node and are directional. The NDA score is the sum of the −𝑙𝑜𝑔./ 𝑝  values for a node in the 
chosen subset and all other nodes within the subset. The NDA score therefore quantifies the 
density of this subset of nodes in network space. The purpose of using the empirical probability of 
a correlation, rather than the raw correlation metric, is to control for bias in favour of highly-170 
connected nodes, as would occur if one expression profile were very common. Finally, the NDA 
score is assigned its own 𝑝 -value by comparison to that obtained using randomly permuted 
subsets (see below). If the network contains no additional information about this subset of nodes, 
then the relationships between nodes in the chosen subset will be no stronger than the 
relationships seen in permuted subsets. 
Application to coexpression of regulatory regions 
From the set of all nodes in a network, a subset is selected because they share some 
characteristic. In the case of the genomic analyses reported here, the nodes are TSS, and the 
subset of interest is those TSS that contain a variant that has some evidence of association with a 
particular trait. Throughout this paper, we have defined the set of phenotype-associated 180 
transcription start sites, 𝑅, as follows: the set of regulatory elements associated with phenotype-
associated single nucleotide polymorphism within 300bp (promoters) or 0bp (enhancers) upstream 
from a FANTOM5 transcription start site (TSS) and 100bp (promoters) or 0bp (enhancers) 
downstream. In order to enable the detection of new associations, we use a deliberately 
permissive threshold. We define as “putatively-significant” a SNP-phenotype association of 𝑝 <
5×1078. Let the integer variable 𝑖 be used to index the base pairs (bp) of the genome. For a given 
trait, the set of input SNPs, 𝐾, are those that have a putatively-significant association with that trait 
at our chosen threshold. If we let 𝑇𝑆𝑆=>?@> equal the base pair index 300bp (promoters) or 0bp 
(enhancers) upstream from a FANTOM5 transcription start site (TSS) and 𝑇𝑆𝑆ABC  100bp 
(promoters) or 0bp (enhancers) downstream, the set, 𝑃, of putative trait-associated promoters is 190 
given by: 
𝑃 = {𝑖: 𝑖 ∈ 𝐾, 𝑇𝑆𝑆=>?@> − 300 ≤ 𝑖 ≤ 𝑇𝑆𝑆ABC + 100} 
and the set 𝐸 of enhancers containing a putative trait-associated SNP is given by: 
𝐸 = {𝑖: 𝑖 ∈ 𝐾, 𝑇𝑆𝑆=>?@> ≤ 𝑖 ≤ 𝑇𝑆𝑆ABC} 
giving a total set of regulatory regions: 
𝑅 = 𝑃 ∪ 𝐸 
Linkage disequilibrium (LD) - grouping nearby regulatory regions 
Input SNPs from GWAS results tend to be in LD with nearby variants. There is therefore a risk of 
spurious coexpression, since nearby regulatory regions are also likely to share regulatory 
influences, such as chromatin accessibility, enhancers, and lncRNAs. One solution to this would be 200 
to filter input SNPs by LD. However this would require that LD relationships for all SNPs be known 
for all of the populations from which SNP association data were derived, which is not the case. It 
would also risk removing functionally important regulatory regions from the analysis, by choosing 
only one SNP per LD block. 
In order to overcome these problems, we sought to identify those regulatory region-associated 
SNPs within a given region that are most likely to contribute to a given subnetwork of putative 
phenotype-associated regulatory regions. By the definitions described above, these will be those 
regulatory regions with the highest NDA score. Regulatory regions are considered for combination 
if they are separated by 100,000bp or less. If any regulatory region within this range has a 
correlation 𝑝 -value of less than 0.1 with any other regulatory regions in the range, they are 210 
combined. A single representative regulatory region is then chosen - the regulatory region with the 
largest NDA score in the group, derived from a network comprised of all other groups. 
In order to confirm that spurious coexpression signals are not being generated solely because of 
LD, we used the ENSEMBL Perl API for the 1000 genomes phase 3 data (CEU) to search for 
variants in LD with each SNP lying within the chosen regulatory region for each group. Variants in 
LD with a variant in any other chosen regulatory region are reported. 
Coexpression matrix 
𝐴 is defined as the set of all nodes in the whole network. Each member of 𝐴 is a node in an 
interaction network. For each 𝑖 ∈ 𝑅, Spearman’s rank correlation, 𝑥, is calculated with each other 
node in 𝑅. The probability, 𝑝, of a correlation as strong as, or stronger than, the index correlation, 220 
𝑥, arising by a chance pairing between the index node and any other node (𝑛 @ST ) is inferred from 





Network density analysis 
For every node in the set 𝑅, a score 𝑠 is calculated to summarise the strength of interactions with 
all other nodes in 𝑅. Since the only thing that the elements of 𝑅 have in common is that they are 
TSS identified by the set of input SNPs, unexpectedly strong inter-relationships between elements 
of 𝑅 are taken as indirect evidence of a relationship between the input SNPs themselves. The NDA 





Raw 𝑝-values are calculated from the empirical distribution of values of 𝑠  for 10000 permuted 
networks. The Benjamini-Hochberg method is used to estimate false discovery rate (𝐹𝐷𝑅 ). 
Significant network density scores are taken as those with 𝐹𝐷𝑅 < 0.05 . In order to enable 
comparison of coexpression scores between different analyses, the raw coexpression score (𝑠) is 
corrected by dividing by the total number of independent groups of regulatory regions included in 
each analysis, 𝑛@A=, yeilding a corrected coexpression score, 𝑐𝑐𝑠: 
𝑐𝑐𝑠 = 𝑠/𝑛@A= 
Iterative recalculation 
The node in the network with the highest NDA score has, by definition, numerous strong 
correlations with other nodes in the subset 𝑅. The NDA scores assigned to these other nodes are 240 
therefore inflated by their association with the stongest node. This inflation may reflect biological 
reality, since both TSS have a putative genetic association with the phenotype of interest, and both 
share strong links. However, there is a risk that TSS sharing a chance association with a strongly 
coexpressed TSS will be spuriously inflated to significance. For this reason, we have applied a 
stringent correction in order to ensure that we have confidence in each significantly coexpressed 
TSS independently of all TSS with stronger coexpression in the network: the NDA score for each 
TSS is calculated after removing all TSS with stronger NDA scores from the network. 
Input datasets 
Of 267,225 robust promoters and enhancers identified by FANTOM5, 93,558 (50.6%) were 
promoters within 400 bases of the 5′ end of a known transcript model. These were annotated with 250 
the name of the transcript. Alternative promoters were named in order of the highest transcriptional 
activity. Where necessary, coordinates for GWAS SNPs were translated to hg19 coordinates using 
LiftOver, or coordinates were obtained for SNP IDs from dbSNP version 138. 
Permutations 
A circular permutation method was devised to prevent systematic bias by maintaining the 
underlying structure of GWAS SNP data. The NDA score for a given regulatory region was 
compared with NDA scores obtained from randomly permuted subsets of genes to give an 
empirical 𝑝-value for coexpression. If permuted networks consist of randomly-selected regulatory 
regions, then this 𝑝-value quantifies coexpression alone; if the permuted networks are generated 
by mapping randomly-selected SNPs to regulatory regions, then the final 𝑝-value is a composite of 260 
two measures: coexpression, and the enrichment for true GWAS hits in regulatory sequence. 
Pre-mapping permutations 
Pre-mapping permutations use a random set of SNPs generated by rotation of the input set of 
SNPs, 𝐾, on a concatenated circular genome. The choice of background is critical - some more 
recent GWAS studies consider only a subset of variants with a high probability of association with 
a given trait. In the present analyses, background data were chosen to reflect as accurately as 
possible the pool of variants included in the original study. For this reason, results are presented 
only for phenotypes for which the the entire summary dataset was available, including a 𝑝-value for 
every SNP, so that the background used to generate permuted networks is exactly the same 
background from which the real dataset is drawn. 270 
Post-mapping permutations 
In order to quantify the effect of coexpression alone (i.e. eliminating the inflation of NDA scores that 
occurs due to enrichment of trait-associated SNPs in regulatory regions), permuted networks were 
generated after mapping to TSS regions. This is analogous to randomly reassigning the labels in 
the network, but aims to preserve the local relationships between regulatory regions, since we 
cannot assume that regulatory regions are randomly distributed on the genome, and since regional 
regulatory events, such as chromatin reorganisation, are expected to lead to coexpression 
between nearby regulatory regions. 
Where 𝐴 is defined as a list of regulatory regions comprising the whole set of FANTOM5 TSS, 
post-mapping permutations select a subset of 𝐴 in a similar circular manner, by displacing the 280 
members of the set 𝑅 by a random number of places on the list. Where the displacement pushes 
members of 𝑅 off the end of the list, they are re-entered at the beginning. 
This process generates a pool of variants that are likely to be grouped in a similar distribution on 
the genome to the input set. If the input set contains a large group of TSS regions in close 
proximity to each other on the genome, it is likely that this group of TSS regions will be joined as a 
single unit (see above) for analysis. During generation of permutations, the same number of 
consecutive TSS regions elsewhere on the genome may not be in sufficient proximity (and 
expression correlation) to be grouped together. This would create extra network nodes, potentially 
inflating the NDA scores in the permuted sets. To mitigate against this, those TSS from each 
permutation that do not conform to the input set distribution are re-entered into a further circular 290 
permutation until an identical distribution is found. If no matching grouping is found after 8 repeat 
permutations, additional regulatory regions are added from consecutive positions above and below 
whichever group is nearest in size to the relevant group in the original input dataset. 
False discovery rates (FDR) are calculated using the Benjamini-Hochberg method. 
Choice of samples and regulatory regions 
The enrichment for GWAS hits from a pooled resource comprising the NCBI GWAS catalog and 
the GWASdb database (observed 𝑆𝑁𝑃𝑠	𝑝𝑒𝑟	𝑀𝑏 : expected 𝑆𝑁𝑃𝑠	𝑝𝑒𝑟	𝑀𝑏 ) was quantified at 
increasing search window sizes upstream and downstream from the transcription start site (TSS). 
A table of GWAS hits for a broad range of phenotypes was obtained from the NCBI GWAS catalog 
and from a larger, less selective catalog of GWAS 𝑝 -values meeting permissive criteria for 300 
genome-wide significance, GWASdb. The GWASdb dataset is less curated than the NCBI GWAS 
catalog, but contains a much greater range of SNPs since it does not restrict inclusion to the 
strongest associations, or to putative causative variants. Because both databases are limited by 
the variation in reporting, and quality, of the original GWAS studies from which data are drawn, this 
analysis was restricted to variants meeting genome-wide significance at a widely-accepted 
threshold (𝑝 < 5×107f). These catalogues were combined and filtered to remove duplicate entries. 
Data were obtained from: 
• NHGRI GWAS catalog, June 2014 http://www.genome.gov/gwastudies 
• GWASdb2, June 2014 update 
ftp://jjwanglab.org/GWASdb/20140629/gwasdb_20140629_snp_trait.gz 310 
Overlapping phenotypes, such as “urate” and “uric acid” were manually merged. Phenotypes that 
were considered to be too broad to be informative were excluded, as were those that were not 
related to human disease. A complete table of phenotypes in GWASdb and NCBI GWAS catalog, 
showing mergers and inclusion/exclusion in the present work, is provided in a supplementary file 
(SF2_phenotype_matching.txt). 
Anti-correlation 
Strong anti-correlation between pairs of TSS associated with the same phenotype may have 
biological importance, such as down-regulation at one TSS but expression at another, or negative 
regulation of a signalling pathway on which expression of a TSS is dependent. For this reason, 
anti-correlations may improve detection of true associations in this analysis. However, in order to 320 
confer an overall improvement on the performance of the algorithm, true inverse expression 
relationships between phenotype-associated TSS would need to be sufficiently common to 
overcome the noise added by incorporating all strong anti-correlations into the NDA score. Anti-
correlations do not contribute any net improvement to the NDA scores for a training set (Crohn’s 
disease, 50% of all SNPs, chosen at random), and were therefore excluded. 
GWAS data sources 
Full GWAS or meta-analysis data, reporting every SNP genotyped or imputed in a given study, are 
required in order to permute subsets against the appropriate background for a given study. These 
were obtained from the following sources: 
• Crohn’s disease summary 𝑝-values were obtained from the International Inflammatory Bowel 330 
Disease Genetics Consortium ftp://ftp.sanger.ac.uk/pub4/ibdgenetics/cd-meta.txt.gz 
• Ulcerative colitis summary 𝑝-values were obtained from the International Inflammatory Bowel 
Disease Genetics Consortium ftp://ftp.sanger.ac.uk/pub4/ibdgenetics/ucmeta-sumstats.txt.gz 
• Summary 𝑝 -values for human height were obtained from the GIANT consortium 
https://www.broadinstitute.org/collaboration/giant/images/4/47/GIANT_HEIGHT_LangoAllen2
010_publicrelease_HapMapCeuFreq.txt 
• Summary 𝑝-values for total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides 
were obtained from the Global Lipids Consortium 
http://csg.sph.umich.edu/abecasis/public/lipids2013/ 
• Summary 𝑝 -values for systolic and diastolic blood pressure.  were obtained from the 340 
International Consortium on Blood Pressure study 
http://www.georgehretlab.org/icbp_088023401234-9812599.html 
Cell type specificity 
In order to better understand the pathophysiological implications of disease variants in regulatory 
regions, we sought to identify whether these regions exhibit unexpectedly specific expression in 
any given cell types or tissue samples. In order to reduce noise, technical and biological replicates 
were averaged for this and subsequent analyses. The full table of samples in FANTOM5, showing 
which samples were averaged as technical replicates, and which were excluded, is in 
supplementary table 2 (SF2_phenotype_matching.txt). 
For a given trait, we took the subset of regulatory regions for which a significant coexpression 350 
pattern was detected for that trait (coexpression 𝐹𝐷𝑅 ≤ 0.05). For each regulatory region, we 
created a list of all cell types in which that region was active, ranked by expression level. We then 
combined the cell type lists for each regulatory region using a robust rank aggregation (RRA). 
There are several possible sources of bias in this raw measurement. For example, some cell types 
have more cell-type specific transcriptional activity, perhaps because these cell types fulfil a 
specialised role; other cell types are particularly well-represented in the FANTOM5 samples. We 
therefore controlled for the probability that a given cell type would be highly ranked in the initial 
RRA analysis, by permuting RRA results for at least 100,000 random selections of 𝑛 regulatory 
regions. We then calculated the empirical 𝑝-value for each cell type, i.e. the probability that this cell 
type would be assigined a raw RRA 𝑝 -value at least as strong by random chance. We then 360 
corrected for multiple comparisons using the Benjamini-Hochberg method to estimate false 
discovery rate (𝐹𝐷𝑅). 
Code availability 
Computer code required to run the NDA method, specifically for the detection of coexpression in 




Evaluation of the NDA method and FANTOM5 input dataset 
Our initial evaluation demonstrated that coexpression is stronger among regulatory regions 370 
containing variants with low GWAS p-values (Fig 2). The coexpression signal obtained for the test 
input set was evaluated using different subsets of FANTOM5 samples (cell lines, timecourses 
following a perturbation in primary cells or selected cell lines, tissue samples, primary cells, or 
various combinations of these), and different types of regulatory region (enhancers, promoters 
assigned to annotated genes, other promoters, or all regulatory regions combined) (Fig 3). The 
strongest coexpression is seen in the combined sample set. A “minimal detail” sample set was also 
tested, comprising a single average value for each of the timecourses, primary cell types and 
tissue types, and excluding data from unstimulated cell lines. The complete dataset, including all 
cell types and tissues, provided the strongest signal, demonstrating that there is additional 
biologically-relevant information contained in the expression profiles from all sample subsets (Fig 380 
3). 
 
Fig 2. Optimisation of GWAS p-value threshold. Coexpression signals are shown for six different −𝐥𝐨𝐠𝟏𝟎(𝐩) bins 
for GWAS 𝐩 values from a single study of Crohn’s disease. From each bin, 800 SNPs were selected at random. 
No signal for coexpression is detected at weak 𝐩-values.  
 
Fig 3. (a) Enrichment (y axis, observed 𝑺𝑵𝑷𝒔	𝒑𝒆𝒓	𝑴𝒃: expected 𝑺𝑵𝑷𝒔	𝒑𝒆𝒓	𝑴𝒃) at increasing search window sizes 
(x axis) upstream and downstream from the transcription start site (TSS) for increasingly strong GWAS signals 
(z axis, −𝒍𝒐𝒈𝟏𝟎𝒑). (b) Change in coexpression signal using different subsets of the FANTOM5 dataset, using the 
Crohn’s disease GWAS as the input set. Q:Q plots of observed:expected NDA scores obtained using a given 390 
subset of samples (see methods for full description of each subset). Rows indicate the subset of regulatory 
regions used in each analysis. Percentage of significantly coexpressed entities (hits, 𝑭𝑫𝑹 < 𝟎. 𝟎𝟓) and 𝒑-value 
(Kolmogorov-Smirnov test) comparing observed (blue) and expected (red) distributions are shown below each 
plot. 
The difference between the distributions of NDA scores derived from pre- and post-mapping 
permutations reveals the different components of the measure. When compared to a random pool 
of SNPs (pre-mapping permutations), two factors inflate the NDA scores for real GWAS data: 
firstly, more regulatory regions are identified because true GWAS hits are enriched within 
regulatory regions; secondly, the coexpression signal itself is greater for real data. In contrast, 
post-mapping permutations have precisely the same number of regulatory regions included as the 400 
real dataset, so there is no component of inflation due to enrichment in regulatory regions. The 
effects of these different components are shown in Fig 4, which reveals the NDA score to be a 
composite measure of both signals. 
 
Fig 4. (Top panels) Circular plots of coexpression links between different locations on the genome, illustrating 
the spatial separation of highly-correlated regulatory regions. The coloured outer circle shows an end-to-end 
concatenated view of the human chromosomes. The black inner circle shows – 𝒍𝒐𝒈𝟏𝟎  GWAS p-values for 
included SNPs. Links depict an association between two regulatory regions containing these SNPs and are 
coloured according to −𝒍𝒐𝒈𝟏𝟎(𝒑)(line colour indicates – 𝒍𝒐𝒈𝟏𝟎(𝒑): red>3, blue> 𝟐, green> 𝟏. 𝟓). (Bottom panels) 
Quantile-quantile plots showing observed and expected coexpression scores. Expected coexpression scores 410 
are derived from circular permuted subsets of regulatory regions (post-mapping permutations; black circles) or 
SNPs chosen by circular permutations against the background of all SNPs genotyped in each study. Data are 
shown for high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol. See 
supplementary results for full results of all analyses.  
Similar expression profiles are often seen arising from regulatory regions that are close to each 
other on the same chromosome, which may also span linkage disequilibrium blocks. The effect of 
this on the coexpression signal was mitigated by grouping nearby (within 100,000bp) regulatory 
regions into a single unit, unless they have notably different expression patterns. SNPs in nearby 
regulatory regions are also more likely to be in linkage disequilibrium, and these regulatory regions 
themselves are more likely to share cis- (or short-range trans-) regulatory signals in common. We 420 
checked for significant linkage disequilibrium between regulatory regions assigned to independent 
groups. At a threshold of r2 > 0.8, there is no linkage disequilibrium between significantly 
coexpressed groups; three examples of weaker linkage relationships were detected with 0.08 ≤ r2 ≤ 
0.6 (Supplementary results).  
Fine mapping 
Regulatory regions around individual TSS with higher coexpression scores contain variants with 
stronger GWAS p-values (Fig 5a), indicating that this independent signal provides additional 
information that may be used for fine-mapping causative loci (Fig 6; Supplementary results). 
Where data are available, we have compared our results to the recent fine mapping study by 
Huang et al, who use high-resolution genotyping in 67,852 subjects with inflammatory bowel 430 
disease to quantify the probability that a given variant is causal. A total of 9 variants with a causal 
probability > 0.1 lie within 150,000bp of a significantly coexpressed region; of these, 7 lie 
immediately adjacent to the most significantly coexpressed promoter/enhancer in the region.     
 
Fig 5. (a) Relationship between GWAS p-value for a SNP, and coexpression scores of individual promoters 
assigned to that SNP for all phenotypes for which significant coexpression was detected. Top panel: GWAS p-
values (log scale) vs corrected coexpression scores. Bottom panel: linear regression lines for data in top panel; 
Spearman's r and associated p-values are shown for each trait. Only significantly coexpressed (FDR<0.05) 
promoters are included. (b) Rank comparison of named genes compared with gene-level burden of significance 
in original GWAS studies (PASCAL sum genescore). Log rank is shown on each axis (Rank 1 = highest scoring 440 
gene) for the subset of coexpression scores obtained for promoters of named genes. Open squares indicate 
significant coexpression (FDR<0.05). 
Discovery and prioritisation of GWAS hits in regulatory sequence 
In order to enable the detection of new regulatory regions with strong coexpression relationships, 
we chose a permissive threshold at GWAS 𝑝 < 5×1078. GWAS data for Crohn’s disease[16] were 
used for initial optimisation of the NDA approach. Of the 8 GWAS datasets for phenotypes that 
were not used in algorithm development (i.e. all apart from Crohn’s disease), 6 showed evidence of 
significant coexpression (Table 1). Among these, between 17 and 24% of regulatory regions 
identified as containing a GWAS SNP were found to be significantly coexpressed with other 
regulatory elements associated with the same phenotype (FDR < 0.05, compared with 100 450 
permuted subsets of equal size; see Methods). 
Table 1. Results of coexpression analysis for a range of human traits for which high-quality data are available: 
Crohn's disease, ulcerative colitis, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total 
cholesterol,  triglycerides, height, systolic blood pressure (SBP) and diastolic blood pressure (DBP). KS test: 
Kolmogorov-Smirnov test comparing distribution of coexpression scores for this study with permuted values. 
*Initial optimisation and parameterisation of the algorithm was undertaken using a random subset of data from 
this study. 
Although many coexpressed regulatory regions are not promoters for annotated genes 
(supplementary results; Fig 3), we compared the named genes in our results with gene-level 
burden of significance scores from PASCAL[17] analysis of the original GWAS studies. Since the 460 
coexpressed regulatory regions were detected due to the presence of a variant with a low p-value, 
it is expected that the genes with coexpressed promoters will be highly ranked in a gene-level 
analysis. However, the weak but significant correlation (Spearman 𝑟 = 0.30; 	𝑝 = 1.9×107{ ) 
between the approaches provides further evidence that the coexpression signal itself provides 
additional information which successfully prioritises regulatory regions (Fig 5b). 
 
Fig 6. Examples of detail of chromosomal regions surrounding regulatory regions significantly coexpressed in 
ulcerative colitis (TSS+/-150Mb). (a) Region surrounding IL10 (b) Region surrounding C1orf106.  Top panel: 
Coloured rectangles show genomic location of individual regulatory regions (promoters or enhancers). Height 
of regulatory regions on y-axis depicts the coexpression score assigned to this regulatory region; groups of 470 
regulatory regions considered as a single unit (see Methods) share the same colour. Black circles show GWAS 
p-values for individual SNPs. Red circles show causative probabilities estimated by Huang et al for specific 
variants, where available. Bottom panel: genomic locations of known protein coding transcripts in sense (green) 
and antisense (purple). 
For a given disease, regulatory regions containing GWAS variants are coexpressed if they share 
similar activity patterns (i.e. similar expression patterns among transcripts arising from these 
regulatory regions) with other regulatory regions implicated in that disease. Fig 7a shows 
significant coexpression superimposed on a two-dimensional representation of the entire network 
of pairwise correlations. Since activity (transcript expression) was measured in many samples, the 
true proximity of regulatory regions to one another cannot be accurately represented in two 480 
dimensions – a perfect representation would require as many dimensions as there are unique 
samples. In contrast, the NDA method quantifies proximity of regulatory regions in true network 
space without artificial dimensionality reduction. Thus significantly coexpressed elements are 
detected even if they are not directly adjacent on a two-dimensional representation of the network 
(Fig 7).  
 
Fig 7. Examples of detail of chromosomal regions surrounding regulatory regions significantly coexpressed in 
ulcerative colitis ($TSS+/-150Mb$). (a) Region surrounding IL10 (b) Region surrounding C1orf106.  Top panel: 
Coloured ectangles show genomic location of individual regulatory regions (promoters or enhancers). Height of 
regulatory regions on y-axis depicts the coexpression score assigned to this regulatory region; groups of 490 
regulatory regions considered as a single unit (see Methods) share the same colour. Black circles show GWAS 
$p$-values for individual SNPs. Red circles show causative probabilities estimated by Huang \emph{et al} for 
specific variants, where available. Bottom panel: genomic locations of known protein coding transcripts in 
sense (green) and antisense (purple). 
We saw no evidence of spurious coexpression due to genomic proximity with shared regulatory 
influences (see Methods). In each of the GWAS analyses for which significant coexpression was 
detected, strong coexpression links were seen between loci that were widely separated on the 
genome (Fig 4; supplementary results).   
The coexpression signal essentially combines the signal for association in a GWAS with the 
location and activity pattern of regulatory regions on the genome. We deliberately chose a 500 
permissive GWAS p-value threshold in order to enable the detection of new signals that did not 
achieve genome-wide significance in the original studies.  For example, we found that coexpressed 
transcripts for both LDL and total cholesterol (TC) arise from promoters for well-studied genes such 
as APOB[18] and ABCG5[19], but also from regulatory regions not previously associated with 
cholesterol levels. A promoter for SLC22A1, which encodes an organic cation transporter, 
OCT1[20], is strongly coexpressed among elements associated with LDL and TC (Supplementary 
results). OCT1 transcription is regulated by cholesterol[21] and the transporter regulates hepatic 
steatosis through its role in thiamine transport[22]. This action of OCT1 is inhibited by 
metformin[22], an oral hypoglycaemic agent whose cholesterol-lowering effect[23] is not well 
understood[24]. Full results of coexpression analyses are in the supplementary results, and online 510 
at http://baillielab.net/coexpression.  
Cell-type and tissue specificity 
The significantly-coexpressed networks detected here could be regarded as revealing the 
signature expression profile, at least within the FANTOM5 dataset, for a given disease or trait. We 
next explored whether these signature expression patterns reveal cell types or biological 
processes that may contribute to the trait or disease susceptibility.  
We therefore ranked cell types and tissues by transcriptional activity for each of the significantly-
coexpressed loci for each trait, and combined the rankings using a robust rank aggregation[25]. By 
first detecting the characteristic expression signature associated with a given phenotype using only 
high-resolution GWAS data, and then detecting the cell type and tissue activity profiles that 520 
underlie this signature, we improve on the statistical power of previous methods that have 
attempted to detect cell-type specific signatures of disease[4,6,26]. Signals that are strong enough 
to be detected in previous, less powerful studies are highly significant in our analysis; for example 
genetic loci associated with cholesterol are transcriptionally active in hepatocytes and liver 
tissue[6](Supplementary results).  
Discussion 
The development of high-throughput genotyping methods has led to an explosion of associations 
between genetic markers and human diseases[29]. The results presented here are a step towards 
overcoming the next challenge for this field: making sense of these associations to advance the 
practice of medicine. There has been increasing recognition of the potential to utilise prior 530 
knowledge to improve detection and interpretation of genome-wide signals[30]. The results of our 
analysis demonstrate that there is biological information in the coexpression of genetic variants 
associated with a particular disease that can provide the basis for prioritising variants that would 
not otherwise meet standard thresholds for genome-wide statistical significance. 
We report relationships between numerous regulatory regions that are not associated with named 
genes – a restriction that has previously limited the transition from genetic discovery to biological 
understanding[14,31–34]. Our analysis reveals the impact of specific enhancers and promoters 
that may be remote from the genes they regulate, or may contribute to tissue-specific regulation of 
a gene that may otherwise appear to be more widely-expressed.   
Even for those disease-associated variants that can be reliably assigned to a named gene, 540 
previous attempts to draw functional inferences have, by necessity, relied on published data[31], 
annotated biological pathways[35], or gene sets[34,36]. Although many important insights have 
been gained from these approaches, they share a fundamental limitation: reliance on existing 
knowledge. This restricts the ability to exploit the potential of genomics to deliver insights into new, 
previously unseen, mechanisms of disease[37].  
Results for Crohn’s disease and ulcerative colitis were compared to the report by Huang et al[15], 
who used high-resolution genotyping in a large cohort, together with publicly-available functional 
genomics data, to identify immune cell signatures implicated in Crohn’s disease, and gut-specific 
cell types in ulcerative colitis. Our analysis, conducted in parallel and without knowledge of these 
findings, discovered the same associations, but goes further. Firstly, we demonstrate with a higher 550 
level of statistical confidence that these cell type associations are real (supplementary results). 
This is important in itself, because it is consistent with the view that ulcerative colitis, in which 
disease processes are primarily restricted to the colon and rectum, is a consequence of 
dysregulation of processes that are intrinsic to the large bowel, including epithelial barrier 
function[27], whereas Crohn’s disease is a multisystem autoimmune disorder with more diverse 
extra-intestinal manifestations[28], consistent with a primary innate immune aetiology affecting 
monocyte-macrophage differentiation and response to micro-organisms[38].  
Secondly, our analysis extends current knowledge by revealing two distinct groups of significantly-
coexpressed regulatory regions for each of these diseases, with differing expression profiles. For 
Crohn’s disease, one group is restricted to immune cells, particularly monocytes exposed to 560 
inflammatory stimuli, while another group of regulatory regions is active in epithelial cells. In 
contrast, cell type associations with ulcerative colitis were statistically significant in rectum, colon 
and intestine samples, and in a distinct group of immune cells: macrophages exposed to bacterial 
lipopolysaccharide (Fig 7; S5 Table 1.2). Based on the fundamental assumption of coexpression - 
that expression profile relates to function - we interpret this as evidence that two distinct biological 
processes are implicated in each of these diseases. This may be because a “two-hit” mechanism is 
required for disease pathogenesis. Alternatively these distinct processes may indicate genetically- 
(and hence aetiologically-) distinct sub-syndromes, or disease endotypes[39], within both Crohn’s 
disease and ulcerative colitis.  
In either case the predominance of each process in an individual patient is likely to have 570 
therapeutic relevance. For example, the highly variable clinical response to immunomodulatory 
therapies, such as methotrexate[40] or anti-TNF monoclonal antibodies[41], may be influenced by 
the burden of disease-associated variants in Crohn’s disease Group 1 (Fig 7). This represents a 
conceptually new application of network theory to the detection of disease endotypes, and is likely 
to have more direct clinical consequences than other methods[42]. 
The data used for development and testing of the coexpression approach were from large meta-
analyses that incorporate genotyping (or imputation) of genetic variants at extremely high 
resolution, increasing the probability that variants will be found within regulatory regions. In future, 
the availability of whole-genome sequencing can reasonably be expected to produce many 
additional high-quality datasets for coexpression analysis. In principle, the NDA approach can be 580 
generalised to any network in which it is desirable to quantify the proximity of a subset of nodes.  
The scale, depth and breadth of the FANTOM5 expression atlas enable detection of subtle 
coexpression signals for regulatory regions that have previously been undetectable. The NDA 
approach developed here enables the identification of cell types and regulatory regions implicated 
in disease pathogenesis, and contributes a new independent signal to fine mapping of causative 
loci. As additional genetic studies become available at greater genotyping resolution, we anticipate 
that this method will detect new genetic associations with disease and coexpressed modules 
underlying pathogenesis. The NDA method will enable the identification of critical cell types and 
processes implicated in mechanisms of disease, and enable further genetic stratification of disease 








The FANTOM5 atlas is accessible from http://fantom.gsc.riken.jp/data/  
An online service running the coexpression method is available at http://baillielab.net/coexpression   
SUPPORTING INFORMATION LEGENDS 600 
1. SF1_specific_GWAS_results.xlsx Network density analysis results for each of the GWAS 
studies included here.  
2. SF2_phenotype_matching.txt Table of phenotypes in GWAS catalog and GWASdb 
showing combinations of similar/identical phenotypes for use in regional enrichment 
calculations.  
3. SF3_sample_averaging.xlsx Table of FANTOM5 samples showing combinations of similar 
samples that were averaged for use in coexpression network.  
4. SF4_supplementary_fine_mapping_results.pdf Figures for every region included in the 
analyses described in this paper (See Fig 6 in main manuscript for legend). 
5. SF5_supplementary_results.pdf Tables of network density analysis results for each GWAS 610 
studies included here.  
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